RetapamulinPleuromutilin antibiotic,protein synthesis inhibitor CAS# 224452-66-8 |
- SRT1720 HCl
Catalog No.:BCC2222
CAS No.:1001645-58-4
- SRT2104 (GSK2245840)
Catalog No.:BCC1950
CAS No.:1093403-33-8
- Sirtinol
Catalog No.:BCC2224
CAS No.:410536-97-9
- EX 527 (SEN0014196)
Catalog No.:BCC2223
CAS No.:49843-98-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 224452-66-8 | SDF | Download SDF |
| PubChem ID | 23725003 | Appearance | Powder |
| Formula | C30H47NO4S | M.Wt | 517.76 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | SB-275833 | ||
| Solubility | DMSO : ≥ 52 mg/mL (100.43 mM) *"≥" means soluble, but saturation unknown. | ||
| SMILES | CC1CCC23CCC(=O)C2C1(C(CC(C(C3C)O)(C)C=C)OC(=O)CSC4CC5CCC(C4)N5C)C | ||
| Standard InChIKey | STZYTFJPGGDRJD-NJUFAHRVSA-N | ||
| Standard InChI | InChI=1S/C30H47NO4S/c1-7-28(4)16-24(35-25(33)17-36-22-14-20-8-9-21(15-22)31(20)6)29(5)18(2)10-12-30(19(3)27(28)34)13-11-23(32)26(29)30/h7,18-22,24,26-27,34H,1,8-17H2,2-6H3/t18-,19+,20-,21+,22?,24-,26+,27+,28-,29-,30+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Retapamulin(SB-275833) is a topical antibiotic, which binds to both E. coli and S. aureus ribosomes with similar potencies with Kd of 3 nM.
IC50 Value: 3 nM(Kd, E.coli)
Target: Antibacterial
Retapamulin is a topical antibiotic developed by GlaxoSmithKline. Retapamulin(SB-275833) is the first drug in the new class of pleuromutilin antibiotics to be approved for human use.Retapamulin(SB-275833) is marketed as an ointment under the brand names Altabax and Altargo. Retapamulin(SB-275833) is useful for Antibiotics. References: | |||||
Retapamulin Dilution Calculator
Retapamulin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9314 mL | 9.657 mL | 19.314 mL | 38.6279 mL | 48.2849 mL |
| 5 mM | 0.3863 mL | 1.9314 mL | 3.8628 mL | 7.7256 mL | 9.657 mL |
| 10 mM | 0.1931 mL | 0.9657 mL | 1.9314 mL | 3.8628 mL | 4.8285 mL |
| 50 mM | 0.0386 mL | 0.1931 mL | 0.3863 mL | 0.7726 mL | 0.9657 mL |
| 100 mM | 0.0193 mL | 0.0966 mL | 0.1931 mL | 0.3863 mL | 0.4828 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Retapamulin is a pleuromutilin antibiotic [1].
Retapamulin is developed for topical treatment of skin infections which is mainly caused by gram-positive organisms, β-hemolytic streptococci and coagulase-negative staphylococci. Retapamulin is especially used against those drug resistance strains. In the in vitro studies, retapamulin demonstrates potent activity and a broad spectrum. It shows excellent antimicrobial activities against S. aureus, S. epidermidis, S. saprophyticus, S. pyogenes, S. agalactiae and Viridans group streptococci with MIC50 values of 0.06μg/ml, 0.06μg/ml, 0.12μg/ml, 0.008μg/ml, 0.016μg/ml and 0.03μg/ml, respectively. Retapamulin plays its antibiotic role through binding to a unique site of the bacterial ribosome [1, 2].
References:
[1] Jones R N, Fritsche T R, Sader H S, et al. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrobial agents and chemotherapy, 2006, 50(7): 2583-2586.
[2] Rittenhouse S, Biswas S, Broskey J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrobial agents and chemotherapy, 2006, 50(11): 3882-3885.
- Ginsenoside Rg1
Catalog No.:BCN1066
CAS No.:22427-39-0
- Bayogenin methyl ester
Catalog No.:BCN3722
CAS No.:22425-81-6
- 2,2'-Anhydro-5-methyluridine
Catalog No.:BCC8486
CAS No.:22423-26-3
- Incensole
Catalog No.:BCN3831
CAS No.:22419-74-5
- Siramesine hydrochloride
Catalog No.:BCC5134
CAS No.:224177-60-0
- 3-Epiturraeanthin
Catalog No.:BCN5063
CAS No.:22415-24-3
- Cyclobuxine D
Catalog No.:BCC9221
CAS No.:2241-90-9
- Aristola-1(10),8-dien-2-one
Catalog No.:BCN7608
CAS No.:22391-34-0
- 3,8-Di-O-methylellagic acid
Catalog No.:BCN5062
CAS No.:2239-88-5
- Serratenediol
Catalog No.:BCN5061
CAS No.:2239-24-9
- Pedalitin
Catalog No.:BCN3954
CAS No.:22384-63-0
- Bestatin trifluoroacetate
Catalog No.:BCC3909
CAS No.:223763-80-2
- Benfotiamine
Catalog No.:BCC1415
CAS No.:22457-89-2
- MLCK inhibitor peptide 18
Catalog No.:BCC5828
CAS No.:224579-74-2
- Gymnemagenin
Catalog No.:BCN7841
CAS No.:22467-07-8
- 18-Norabieta-8,11,13-trien-4-ol
Catalog No.:BCN5064
CAS No.:22478-65-5
- Vardenafil HCl Trihydrate
Catalog No.:BCC2277
CAS No.:224785-90-4
- Erigeside I
Catalog No.:BCN7172
CAS No.:224824-74-2
- N-(1-hydroxy-2-(hydroxymethyl)-4-(4-octylphenyl)butan-2-yl)acetamide
Catalog No.:BCN1483
CAS No.:2249289-10-9
- IDRA 21
Catalog No.:BCC6974
CAS No.:22503-72-6
- Falcarindiol
Catalog No.:BCN5065
CAS No.:225110-25-8
- Cathepsin Inhibitor 1
Catalog No.:BCC4896
CAS No.:225120-65-0
- 8-Hydroxy-9,10-diisobutyryloxythymol
Catalog No.:BCN7786
CAS No.:22518-08-7
- CTU Guanamine
Catalog No.:BCC8921
CAS No.:22535-90-6
A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus.[Pubmed:25396674]
Adv Skin Wound Care. 2014 Dec;27(12):548-59.
OBJECTIVE: To evaluate the clinical and bacteriological efficacy of topical Retapamulin ointment 1% versus oral linezolid in the treatment of patients with secondarily infected traumatic lesions (SITLs; excluding abscesses) or impetigo due to methicillin-resistant Staphylococcus aureus (MRSA). DESIGN: A randomized, double-blind, double-dummy, multicenter, comparative study (NCT00852540). SETTING: Patients recruited from 36 study centers in the United States. PATIENTS: Patients 2 months or older with SITL (including secondarily infected lacerations or sutured wounds) or impetigo (bullous and nonbullous) suitable for treatment with a topical antibiotic, with a total Skin Infection Rating Scale score of 8 or greater, including a pus/exudate score of 3 or greater. INTERVENTIONS: Patients received Retapamulin ointment 1% (plus oral placebo), twice daily for 5 days or oral linezolid (plus placebo ointment) 2 or 3 times daily for 10 days. MAIN OUTCOME MEASURE: Primary end point: clinical response (success/failure) at follow-up in patients with MRSA at baseline (per-protocol population). Secondary efficacy end points: clinical and microbiologic response and outcome at follow-up and end of therapy; therapeutic response at follow-up. MAIN RESULTS: The majority of patients had SITL (70.4% [188/267] and 66.4% [91/137] in the Retapamulin and linezolid groups, respectively; intent-to-treat clinical population). Clinical success rate at follow-up was significantly lower in the Retapamulin versus the linezolid group (63.9% [39/61] vs 90.6% [29/32], respectively; difference in success rate -26.7%; 95% CI, -45.7 to -7.7). CONCLUSIONS: Clinical success rate at follow-up in the per-protocol MRSA population was significantly lower in the Retapamulin versus the linezolid group. It could not be determined whether this was related to study design, bacterial virulence, or Retapamulin activity.
In Vitro Activity of Retapamulin and Antimicrobial Susceptibility Patterns in a Longitudinal Collection of Methicillin-Resistant Staphylococcus aureus Isolates from a Veterans Affairs Medical Center.[Pubmed:26666950]
Antimicrob Agents Chemother. 2015 Dec 14;60(3):1298-303.
Mupirocin is a topical antimicrobial used to decolonize patients who carry methicillin-resistant Staphylococcus aureus (MRSA), and the topical agent Retapamulin may be a potential alternative therapy. The goal of this study was to determine the in vitro activity of Retapamulin as well as a panel of 15 antimicrobial agents, including mupirocin, for 403 MRSA isolates collected longitudinally from a naive population at the Veterans Affairs Puget Sound Health Care System. The MICs for Retapamulin had a unimodal distribution, ranging from 0.008 to 0.5 mug/ml. One isolate had an MIC of >16 mug/ml, was also resistant to clindamycin and erythromycin, and was recovered from the nares of a patient undergoing hemodialysis. Twenty-four isolates (6%) and 11 isolates (3%) demonstrated low-level resistance (MICs of 8 to 64 mug/ml) and high-level resistance (MICs of >/= 512 mug/ml), respectively, to mupirocin. Isolates were recovered from 10 patients both before and after mupirocin therapy. Of those, isolates from 2 patients demonstrated MIC changes postmupirocin therapy; in both cases, however, strain typing demonstrated that the pre- and postmupirocin strains were different. A total of 386 isolates (96%) had vancomycin MICs of Retapamulin (0.25%) Although the use of mupirocin is currently the standard therapy for decolonization practices, the activity of Retapamulin warrants its consideration as an alternative therapy in MRSA decolonization regimens.
In Vitro Antimicrobial Activities of Fusidic Acid and Retapamulin against Mupirocin- and Methicillin-Resistant Staphylococcus aureus.[Pubmed:26512169]
Ann Dermatol. 2015 Oct;27(5):551-6.
BACKGROUND: The in vitro activities of Retapamulin and fusidic acid against clinical isolates of mupirocin-resistant and methicillin-resistant Staphylococcus aureus (MRSA) from Korea are not well understood. OBJECTIVE: This study aimed to determine the activities of Retapamulin and fusidic acid against clinical isolates of mupirocin-resistant MRSA. METHODS: Clinical isolates of mupirocin-resistant MRSA were collected from two tertiary hospitals. The minimal inhibitory concentrations of mupirocin, fusidic acid, and Retapamulin were determined using agar dilution method. Polymerase chain reaction was used to confirm the identity of the species and the presence of resistance genes. Pulsed-field gel electrophoresis (PFGE) patterns of chromosomal DNA were used to determine the genetic similarity of high-level mupirocin-resistant isolates. RESULTS: Of the 497 MRSA isolates tested, 22 (4.4%) were mupirocin-resistant. Of these, 9 (1.8%) and 13 (2.6%) had high-level and low-level mupirocin resistance, respectively. Analysis of the PFGE patterns of the high-level mupirocin-resistant MRSA isolates identified five clusters. All 13 of the low-level mupirocin-resistant isolates were resistant to fusidic acid but susceptible to Retapamulin. However, among the 9 high-level mupirocin-resistant isolates, 56% were resistant to fusidic acid, and all were susceptible to Retapamulin. CONCLUSION: Retapamulin is highly active in vitro against Korean clinical isolates of high-level mupirocinand methicillin-resistant Staphylococcus aureus with different genetic backgrounds. Fusidic acid is more active against high-level mupirocin-resistant MRSA than low-level mupirocin-resistant MRSA.
